The most polymorphic genes in the human genome are found at the three classical leukocyte antigen class I (HLA-I) loci: HLA-A, HLA-B, and HLA-C. HLA-A molecules, expressed on the cell surface, present peptide ligands derived from endogenous proteins to the immune system. Foreign peptides presented by HLA-I molecules are recognized by rearranged T-cell receptors (TCRs) on cytotoxic CD8+ T cells.
In parallel, HLA-I molecules also engage with germline-encoded killer-cell immunoglobulin-like receptors (KIRs) on natural killer (NK) cells. NK cells play a key role in the innate immune response, particularly in the early defense against viral infections and in tumor surveillance. They rely on a diverse repertoire of activating and inhibitory receptors to assess and respond to the status of target cells.
Approximately half of the human population carries specific HLA-A and HLA-B alleles capable of inhibiting NK cell activation through interactions with inhibitory KIRs. In contrast, all HLA-C alleles are recognized by inhibitory KIRs, underscoring the central role of the KIR/HLA-C axis in regulating NK cell activity in humans. Although KIR interactions with HLA-I molecules are less peptide-specific than the antigen recognition by TCRs, they still exhibit peptide-dependent binding, highlighting the crucial role of the presented ligand in modulating KIR engagement and its association with human disease.
In this project, we aim to determine whether KIR activation is altered in different solid tumors and to what extent such alterations may be due to modified HLA-C ligandomes. Furthermore, we seek to identify the underlying molecular mechanisms that govern HLA-C peptide quality.
Interferon (IFN) type III (IFN-λ) acts as a first line of defense against pathogens at mucosal surfaces, without triggering the harmful immune responses that can be associated with IFN type I (including IFN-α) (Ye, Schnepf, Staeheli, Nature Reviews Immunology, 2019). The importance of IFN-λ–mediated immune responses has already been demonstrated against various viruses, bacteria, fungi, and parasites that infect the respiratory, gastrointestinal, or reproductive tract.
Helicobacter pylori (H. pylori) is a gram-negative, rod-shaped bacterium adapted to the acidic environment of the human stomach. It is typically transmitted via the fecal-oral route, colonizing and infecting the gastric mucosa. Infection can be associated with a range of diseases, including gastritis, peptic ulcers, and gastric cancer. The WHO has classified H. pylori as a Group 1 carcinogen. Patients with gastric cancer generally have low survival rates. Although established antibiotic treatments are generally effective, the increasing problem of antibiotic resistance makes treatment more difficult. This highlights the urgent need for effective prevention or eradication of H. pylori and development of novel therapeutic strategies.
To date, the potential role of IFN-λ in the control of H. pylori infection has not been investigated. This project focuses on IFN-λ as a protective factor against gastric inflammation and stomach cancer induced by (chronic) H. pylori infection.